2922-45-4

Basic information

• Product Name: 3-Pyridinesulfonamide
• Synonyms: 3-Pyridinesulfonamide;3-Pyridinesulfonamide(7CI,9CI);pyridine-3-sulfonic acid amide;3-Sulphamoylpyridine, 3-(Aminosulphonyl)pyridine;Pyridine-3-sulphonamide 98%
• CAS NO: 2922-45-4
• Molecular Formula: C₅H₆N₂O₂S
• Molecular Weight: 158.17834
• Product Categories: SULFONAMIDE
• Mol File: 2922-45-4.mol
• Article Data: 16

Chemical Properties

• Melting Point: 110-111 °C
• Boiling Point: 357.711 °C at 760 mmHg
• Flash Point: 170.138 °C
• Appearance: /
• Density: 1.417 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.577
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 9.43±0.60(Predicted)
• CAS DataBase Reference: 3-Pyridinesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinesulfonamide(2922-45-4)
• EPA Substance Registry System: 3-Pyridinesulfonamide(2922-45-4)

Safety Data

• Hazardous Substances Data: 2922-45-4(Hazardous Substances Data)

Usage

General Description

3-Pyridinesulfonamide is a chemical compound that belongs to the class of pyridine derivatives. It consists of a pyridine ring with a sulfonamide group attached to it. This chemical is commonly used as a building block in the synthesis of various pharmaceuticals, including potential therapeutic agents for the treatment of various diseases. It has been studied for its antibacterial, antifungal, and anti-inflammatory properties. Additionally, 3-Pyridinesulfonamide has also been investigated for its potential use as a corrosion inhibitor in metal alloys. Overall, it is a versatile compound with potential applications in the field of medicinal chemistry and materials science.

InChI:InChI=1/C5H6N2O2S/c6-10(8,9)5-2-1-3-7-4-5/h1-4H,(H2,6,8,9)

Upstream product

• 636-73-7 3-pyridinesulfonic acid 
• 60-29-7 diethyl ether 
• 75-09-2 dichloromethane 
• 42899-76-3 pyridine-3-sulfonyl chloride hydrochloride 
• 110-86-1 pyridine 
• 16133-25-8 Pyridine-3-sulfonyl chloride 

Downstream Products

• 128924-71-0 C₁₂H₁₀ClN₃O₃S 
• 68498-70-4 pyridine-3-sulfonamide N-oxide 
• 881408-61-3 tert-butyl [2-[3'-(isopropylthio)-4'-[[(3-pyridylsulfonyl)amino]carbonyl]-4-biphenylyl]-ethyl][(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)-ethyl]carbamate 
• 1609109-59-2 C₃₃H₄₁N₅O₅S 
• 1071519-10-2 pyridine-3-sulfonic acid {3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}amide 
• 33003-64-4 5-(aminosulfonyl)-2-methylpyridine-N-oxide 

Relevant articles and documents

Electrochemically generatedN-iodoaminium species as key intermediates for selective methyl sulphonylimination of tertiary amines

Reported herein is a straightforward protocol for approachingN-sulphonylamidinesviaan electricity-driven, iodine-mediated cross dehydrogenative condensation (CDC) between sulphonamides and tertiary amines, which features exclusive N-CH3selectivity for the amine partners. Mechanistic studies indicate that anin situgeneratedN-iodoaminium species serves as the key intermediate.

THIAZOLIDINONE COMPOUNDS AND USE THEREOF

A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

SULFONYLAMINOCARBONYL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USES THEREOF

This disclosure is related to a sulfonylaminocarbonyl derivative of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the sulfonylaminocarbonyl derivatives of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in treating FXR and/or TGR5 mediated diseases, including primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity, etc.